Stop Drug Trials in China: Matas

By Sanders, Carol | Winnipeg Free Press, August 1, 2012 | Go to article overview
Save to active project

Stop Drug Trials in China: Matas


Sanders, Carol, Winnipeg Free Press


City lawyer fears use of executed prisoners' organs

A Winnipeg human rights lawyer is trying to prevent a Canadian drug company from testing its kidney-transplant medication in China where prisoners -- not voluntary donors -- provide most organs.

"I'd like them to stop," said David Matas, who's written to the Edmonton company asking it not to do the drug trial in China, and to the authorities in Canada and the United States asking them not to accept the trial's results.

Edmonton-based Isotechnika Pharma Inc. is about to commence clinical trials of the anti-rejection drug Voclosporin in kidney transplant patients in China with the Chinese company 3SBio.

"China has a system that's neither transparent nor accountable," said Matas. Ethically, anybody involved in these trials has to wonder about the source of transplanted organs, he said.

"The government of China acknowledges, literally, all organs come from prisoners," said Matas, citing quotes by Chinese deputy Minister of Health Huang Jiefu. "In China, more than 90 per cent of transplanted organs are obtained from executed prisoners," the minister reportedly said in 2008.

Matas and Ontario Liberal MP David Kilgour say the bulk of prisoners are locked up for practising Falun Gong, a physical and meditative form of spirituality banned in China.

The head of the Canadian drug company said he knows there are concerns about China but he's certain the trial will be conducted ethically.

"In the transplant world, it has been known for a long time that things can be a little bit iffy when it comes to organ transplant in China," said Isotechnika chairman and CEO Robert Foster in Edmonton.

"One thing we've prided ourselves on being is a really, highly reputable company," he said.

In China, Isotechnika will only test its drug on people who received an organ transplant donated by a living relative, he said, and they will test tissue samples to make sure they're a match.

"We're going to set the bar really high," said Foster. The company is spending $60 million on the trial and doesn't want to throw it away on test results that go "up in smoke," said Foster.

"It doesn't make sense," he said.

But with no accountability or transparency in China, Matas maintains there's no way the Edmonton company or drug-approving authorities can be sure of the source of the organs.

"There is nothing now in place, as far as we can see, that would allow your agency to be satisfied beyond a reasonable doubt that the sourcing of the organs for the clinical trials of Voclosporin is proper," he said in a letter to Health Canada and the U.

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
Loading One moment ...
Project items
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

Cited article

Stop Drug Trials in China: Matas
Settings

Settings

Typeface
Text size Smaller Larger
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

While we understand printed pages are helpful to our users, this limitation is necessary to help protect our publishers' copyrighted material and prevent its unlawful distribution. We are sorry for any inconvenience.
Full screen

matching results for page

Cited passage

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

Cited passage

Welcome to the new Questia Reader

The Questia Reader has been updated to provide you with an even better online reading experience.  It is now 100% Responsive, which means you can read our books and articles on any sized device you wish.  All of your favorite tools like notes, highlights, and citations are still here, but the way you select text has been updated to be easier to use, especially on touchscreen devices.  Here's how:

1. Click or tap the first word you want to select.
2. Click or tap the last word you want to select.

OK, got it!

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.

Are you sure you want to delete this highlight?